Wantao Wu

3.5k total citations · 5 hit papers
44 papers, 2.3k citations indexed

About

Wantao Wu is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wantao Wu has authored 44 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 19 papers in Oncology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wantao Wu's work include Immune cells in cancer (19 papers), Ferroptosis and cancer prognosis (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Wantao Wu is often cited by papers focused on Immune cells in cancer (19 papers), Ferroptosis and cancer prognosis (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Wantao Wu collaborates with scholars based in China, United States and United Kingdom. Wantao Wu's co-authors include Quan Cheng, Hao Zhang, Zeyu Wang, Nan Zhang, Ziyu Dai, Zhixiong Liu, Liyang Zhang, Wenjing Zeng, Peng Luo and Zaoqu Liu and has published in prestigious journals such as Hepatology, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Wantao Wu

43 papers receiving 2.3k citations

Hit Papers

Glioma targeted therapy: insight into future of molecular... 2021 2026 2022 2024 2022 2021 2023 2023 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Glioma targeted therapy: insight into future of molecular approaches
    2022 458 citations Keyang Yang, Zhijing Wu et al. Molecular Cancer profile →
  2. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
    2021 372 citations Hao Zhang, Ziyu Dai et al. Journal of Experimental & Clinical Cancer Research profile →
  3. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials
    2023 228 citations Hao Zhang, Zhe Chen et al. Molecular Cancer profile →
  4. Patient-derived xenograft models in cancer therapy: technologies and applications
    2023 213 citations Wantao Wu, Changjing Cai et al. profile →
  5. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
    2022 174 citations Hao Zhang, Chao Liu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wantao Wu China 19 927 830 700 635 595 44 2.3k
Ziyu Dai China 25 995 1.1× 574 0.7× 700 1.0× 762 1.2× 639 1.1× 84 2.3k
Marta Pàez‐Ribes United Kingdom 15 1.9k 2.0× 1000 1.2× 465 0.7× 452 0.7× 1.1k 1.8× 18 3.2k
Paul Mulholland United Kingdom 24 736 0.8× 853 1.0× 679 1.0× 472 0.7× 458 0.8× 48 2.7k
Takafumi Sangai Japan 26 877 0.9× 979 1.2× 350 0.5× 317 0.5× 444 0.7× 78 2.1k
Jaclyn Sceneay Australia 18 1.2k 1.3× 1.4k 1.7× 1.0k 1.4× 607 1.0× 756 1.3× 21 2.7k
Mari Iida United States 30 1.5k 1.6× 1.3k 1.6× 456 0.7× 620 1.0× 429 0.7× 62 2.8k
William Cruz‐Muñoz Canada 18 1.4k 1.5× 1.1k 1.3× 263 0.4× 471 0.7× 961 1.6× 23 2.5k
Leticia Oliveira‐Ferrer Germany 25 1.4k 1.5× 712 0.9× 458 0.7× 362 0.6× 645 1.1× 76 2.3k
Peter Kabos United States 31 1.0k 1.1× 1.5k 1.8× 206 0.3× 828 1.3× 740 1.2× 100 2.5k
Nicholas M. Donin United States 13 1.3k 1.4× 1.1k 1.3× 204 0.3× 404 0.6× 723 1.2× 25 2.6k

Countries citing papers authored by Wantao Wu

Since Specialization
Citations

This map shows the geographic impact of Wantao Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wantao Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wantao Wu more than expected).

Fields of papers citing papers by Wantao Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wantao Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wantao Wu. The network helps show where Wantao Wu may publish in the future.

Co-authorship network of co-authors of Wantao Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wantao Wu. A scholar is included among the top collaborators of Wantao Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wantao Wu. Wantao Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Ying, Xinyue Xu, Yinghui Peng, et al.. (2025). CircFLNB upregulated by chemotherapy via alternative splicing suppresses the progression of colorectal cancer. Cancer Letters. 631. 217932–217932. 1 indexed citations
2.
Wen, Jie, Yanlin Yang, Hao Zhang, et al.. (2025). PM2.5 increases the risk of early-onset COPD mediated by smoking and shared genes: a large-scale genetic analysis. Clinical and Experimental Medicine. 25(1). 116–116. 1 indexed citations
3.
Li, Zhihao, Jie Wen, Wantao Wu, et al.. (2024). Causal relationship and shared genes between air pollutants and amyotrophic lateral sclerosis: A large‐scale genetic analysis. CNS Neuroscience & Therapeutics. 30(7). e14812–e14812. 4 indexed citations
4.
Wu, Wantao, et al.. (2024). Single-cell analysis identified PDIA3 as regulator of malignant characteristics and macrophage function in human cancers. Functional & Integrative Genomics. 24(4). 136–136.
5.
Zhang, Nan, Hao Zhang, Zaoqu Liu, et al.. (2023). An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms. Cell Proliferation. 56(4). e13409–e13409. 46 indexed citations
6.
Qin, Yiming, Xiongbing Zu, Yin Li, et al.. (2023). A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer. iScience. 26(9). 107722–107722. 8 indexed citations
7.
8.
Zhang, Hao, Zhe Chen, Chao Liu, et al.. (2023). Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Molecular Cancer. 22(1). 159–159. 228 indexed citations breakdown →
9.
Zhang, Hao, Nan Zhang, Ziyu Dai, et al.. (2022). Hyaluronic acids mediate the infiltration, migration, and M2 polarization of macrophages: evaluating metabolic molecular phenotypes in gliomas. Molecular Oncology. 16(22). 3927–3948. 13 indexed citations
10.
Zeng, Wenjing, He Li, Wantao Wu, et al.. (2022). A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma. Journal of Oncology. 2022. 1–16. 3 indexed citations
11.
Zhang, Jingwei, Zeyu Wang, Xun Zhang, et al.. (2022). Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer. Frontiers in Immunology. 13. 810471–810471. 35 indexed citations
12.
Chen, Yu, Jialin He, Rui Chen, et al.. (2022). Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy. Frontiers in Immunology. 13. 881722–881722. 10 indexed citations
13.
Yang, Keyang, Zhijing Wu, Hao Zhang, et al.. (2022). Glioma targeted therapy: insight into future of molecular approaches. Molecular Cancer. 21(1). 39–39. 458 indexed citations breakdown →
14.
Chen, Rui, Wantao Wu, Zhipeng Wen, et al.. (2022). A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis. Frontiers in Immunology. 13. 831542–831542. 18 indexed citations
15.
Zhang, Hao, Wantao Wu, Zeyu Wang, et al.. (2022). Immune Characteristics of LYN in Tumor Microenvironment of Gliomas. Frontiers in Cell and Developmental Biology. 9. 760929–760929. 5 indexed citations
16.
Chen, Rui, Wantao Wu, Tao Liu, et al.. (2022). Large-scale bulk RNA-seq analysis defines immune evasion mechanism related to mast cell in gliomas. Frontiers in Immunology. 13. 914001–914001. 9 indexed citations
17.
Chen, Rui, Xinxing Wang, Ziyu Dai, et al.. (2021). TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas. Frontiers in Immunology. 12. 713757–713757. 22 indexed citations
18.
Zhang, Hao, Yulai Zhou, Xinxing Wang, et al.. (2021). B2M overexpression correlates with malignancy and immune signatures in human gliomas. Scientific Reports. 11(1). 5045–5045. 43 indexed citations
19.
Zhang, Hao, Ziyu Dai, Wantao Wu, et al.. (2021). Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research. 40(1). 184–184. 372 indexed citations breakdown →
20.
Zhang, Hao, Zeyu Wang, Ziyu Dai, et al.. (2021). Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer. Frontiers in Immunology. 12. 694490–694490. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ziyu Dai Breakdown of academic impact, for papers by Marta Pàez‐Ribes Breakdown of academic impact, for papers by Paul Mulholland Breakdown of academic impact, for papers by Takafumi Sangai Breakdown of academic impact, for papers by Jaclyn Sceneay Breakdown of academic impact, for papers by Mari Iida Breakdown of academic impact, for papers by William Cruz‐Muñoz Breakdown of academic impact, for papers by Leticia Oliveira‐Ferrer Breakdown of academic impact, for papers by Peter Kabos Breakdown of academic impact, for papers by Nicholas M. Donin
Rankless by CCL
2026